vTv Therapeutics’ (VTVT) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report report published on Wednesday,Benzinga reports. BTIG Research currently has a $57.00 price target on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Zacks Research upgraded vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. Rodman & Renshaw initiated coverage on vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price on the stock. Finally, Weiss Ratings cut vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Price Performance

Shares of VTVT opened at $26.54 on Wednesday. The firm has a 50-day simple moving average of $31.45 and a two-hundred day simple moving average of $33.35. The stock has a market cap of $104.57 million, a PE ratio of -25.04 and a beta of 0.21. vTv Therapeutics has a 1-year low of $19.50 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, sell-side analysts expect that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.